Novo Nordisk A/S (NVO) Wins U.S. Wegovy Approval for MASH, Expands to China Market

We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Novo Nordisk A/S is one of them.

Novo Nordisk A/S (NYSE:NVO), a global pharmaceutical leader in diabetes and obesity care, continues to strengthen its position with new clinical data, expanded market approvals, and strategic investments in innovation. The company, known for blockbuster drugs Wegovy and Ozempic, is also extending its reach into cardiovascular and rare disease treatments while preparing for a leadership transition.

At the European Society of Cardiology Congress 2025, Novo Nordisk A/S (NYSE:NVO) is set to present fresh data highlighting the cardiovascular benefits of Wegovy and Ozempic, reinforcing their role not just in weight and glucose management but also in broader heart health. In a major regulatory milestone, Wegovy won U.S. approval for treating metabolic dysfunction-associated steatohepatitis (MASH) and secured approval for sale in China, unlocking significant new market opportunities.

The company’s pipeline is advancing rapidly. A late-stage candidate, CagriSema, combining semaglutide with amylin and calcitonin receptor agonists, could represent the next breakthrough in obesity care, while early trials of amycretin have shown strong appetite suppression and weight loss effects. These programs highlight the company’s commitment to sustaining leadership in obesity innovation, making NVO one of the best pharmaceutical stocks to watch closely.

Beyond drug development, Novo Nordisk A/S (NYSE:NVO) is leveraging technology and partnerships to boost growth. A collaboration with Nvidia aims to accelerate drug discovery through artificial intelligence, while the launch of NovoCare Pharmacy provides more affordable access to Wegovy via home delivery.

Looking ahead, the business faces a leadership transition as CEO Lars Fruergaard Jørgensen prepares to step down. At the same time, the firm is pursuing acquisitions in cardiovascular and rare blood disorders, underscoring its ambition to diversify beyond diabetes and obesity and secure long-term growth.

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.